Condition: Cancer · Sponsor: Ruijin Hospital
ASCEND-PANCREATIC is a prospective, multi-omics, observational study aimed at early detecting pancreatic cancer by combined assays for biomarkers of cfDNA methylation, circulating tumor DNA (ctDNA) mutation, serum protein markers and blood miRNA markers, in which of 7,062 participants will be enrolled. The development and validation of the model will be conducted in participants with early stage cancers or benign diseases, along with healthy individuals. The performance of the pancreatic cancer detection test will be evaluated in participants with high risk of pancreatic cancer.
This description comes directly from the study's public registry record.
Qian Zhan, M.D. · +86-021-64370045 ext. 670903 · zhanxi80@126.com
Yuzi Zhang, M.D. · +86-021-60293798 · Z_Zhangyuzi@163.com
Always discuss trial participation with your own doctor first.
| Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
| Huashan Hospital, Fudan University | Shanghai, Shanghai Municipality, China | Active Not Recruiting |
| Zhongshan Hospital, Fudan University | Shanghai, Shanghai Municipality, China | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05556603